NEW YORK, June 25, 2026 /PRNewswire/ -- LinqAlpha, the AI company building the first multi-agent AI system for public markets, today announced that it has been named Best AI Solution at the 2026 Hedge Fund Services Awards, presented by With Intelligence.
The Hedge Fund Services Awards recognize the service providers driving innovation, operational excellence, and sustainable growth across the hedge fund industry. Winners are selected by an independent panel of senior industry leaders, including COOs, CFOs, CTOs, CCOs, and General Counsel from leading investment firms.
LinqAlpha was recognized for its innovative application of AI to institutional investment workflows. Its multi-agent platform helps investment firms transform fragmented market intelligence, research, meetings, and proprietary data into a searchable institutional knowledge base.
LinqAlpha supports investment workflows across asset classes, including equities, macro, credit, and multi-asset strategies. More than 70 financial institutions across North America, Europe, and Asia use LinqAlpha to support investment workflows across asset classes.
"This award is a strong validation of our vision to build the AI operating system for public markets," said Hojun Choi, Co-Founder and CEO of LinqAlpha. "Investment professionals face an overwhelming volume of information every day. We believe the future of investment research is not a single AI assistant, but teams of specialized AI agents working alongside investors as an institutional second brain. We are honored to be recognized by With Intelligence and grateful to the clients who continue to partner with us as we build that future."
About LinqAlpha
LinqAlpha is a New York-based AI company co-founded by former Goldman Sachs analysts and MIT computer science PhDs. The company is building the first multi-agent AI system purpose-built for public markets.
LinqAlpha has been featured by TechCrunch and Forbes for outperforming NVIDIA and OpenAI in industry benchmark evaluations. Today, more than 70 financial institutions across North America, Europe, and Asia use the platform to support investment research and decision-making.
For more information, visit www.linqalpha.com.
About With Intelligence
With Intelligence is a leading provider of investment intelligence, data, events, and networking opportunities for the global asset management industry. The Hedge Fund Services Awards recognize outstanding service providers delivering innovation, client service, and business impact across the investment ecosystem.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
LinqAlpha Wins Best AI Solution at the 2026 Hedge Fund Services Awards
Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies
SHANGHAI, June 25, 2026 /PRNewswire/ -- ATLATL Innovation Center ("ATLATL"), a global innovation platform for life science research and development, and Samsung Bioepis Co., Ltd., today announced the launch of the Samsung Bioepis Innovation Prize C-Lab Outside (Innovation Prize), an open innovation initiative designed to identify and support promising early-stage biotech companies across the Asia-Pacific region.
Applications for the Innovation Prize will open on June 25, 2026.
The program seeks innovative startups and emerging biotech companies working in the following therapeutic areas:
- Oncology
- Immunology & Inflammation (I&I)
- Metabolic Disease
Areas of particular interest include:
- Novel/New Mechanisms of Action (MoA)-based Antibody-Drug Conjugate (ADC)/ X-Drug Conjugates (XDC) (i.e., Payload, Linker, Conjugation)
- Antibody Engineering Technology
- New Modality (Biologics)
- Peptide (Design Engineering, Long-acting Peptide)
- Novel Target Discovery Platform
Selected companies will gain access to ATLATL's world-class laboratory infrastructure, entrepreneurial resources, and industry mentorship. In addition, awardees will have the opportunity to engage with Samsung Bioepis through its open innovation platform, enabling scientific collaboration, technology assessment, and potential future partnership opportunities. Together, these resources are designed to accelerate innovation and support the translation of promising technologies toward commercialization.
"Innovation thrives when visionary science is matched with the right support and opportunities," said Min Jeong Seo, Vice President and Leader of Open Innovation Team at Samsung Bioepis. "Through the Innovation Prize, we are seeking to empower promising biotech entrepreneurs and researchers who are advancing novel approaches to address unmet medical needs. By fostering collaboration across the Asia-Pacific region, we hope to help accelerate scientific innovation and contribute to a strong ecosystem for the development of future medicines."
"Great science alone does not create successful biotech companies," said Dr. PC Zhu, Founder and CEO of ATLATL. "Innovators need access to world-class infrastructure, R&D ecosystem, experienced mentors, strategic partners, and capital to move forward. By bringing together Samsung Bioepis' global development expertise and ATLATL's innovation ecosystem, we hope to provide early-stage biotech entrepreneurs with the resources and support needed to accelerate innovation and deliver meaningful impact to patients."
The Samsung Bioepis Innovation Prize C-Lab Outside reflects both organizations' commitment to advancing open innovation and supporting the next generation of biotechnology entrepreneurs. By bringing together scientific talent, development expertise, and critical infrastructure, the program aims to accelerate the translation of breakthrough research into transformative therapies for patients worldwide. The Innovation Prize is also part of Samsung Bioepis C-Lab Outside, Samsung Bioepis' open innovation program designed to discover, nurture, and collaborate with competent and prospective biotech ventures and startups in and outside of Korea.
About ATLATL
As a global innovation platform for life science research and development, ATLATL has established research centers in Beijing, Shanghai, Shenzhen, Singapore, Hong Kong, and other strategic locations.
ATLATL provides clients with comprehensive research and development services covering various stages, including in vitro drug screening, in vivo disease model establishment, and efficacy evaluation. ATLATL also supports key applications such as large molecule, small molecule, nucleic acid drugs, gene and cell therapy, drug delivery, as well as cutting-edge fields like multi-omics, gene editing, organoids, and organ-on-a-chip. Additionally, ATLATL provides an outstanding experimental environment and professional operational management for scientific researchers.
Through in-depth cooperation with leading global enterprises and research institutions, ATLATL continuously integrates research and development resources and promotes the sharing of new technologies. With advanced systematic research and development models, ATLATL accelerates the engineering process of life sciences, enabling scientific research results to be rapidly and efficiently translated into clinical practice, and contributing to life science innovation and public health on a global level.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
ATLATL and Samsung Bioepis Launch 'Samsung Bioepis Innovation Prize C-Lab Outside' to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific
